Today: 8 February 2026
Subscribe
Browse Category

NYSE:TDG News 17 January 2026 - 4 February 2026

TransDigm (TDG) stock falls again as Baird downgrade keeps pressure on share price

TransDigm (TDG) stock falls again as Baird downgrade keeps pressure on share price

TransDigm shares fell 2.3% to $1,271.89 Wednesday after Baird downgraded the stock and cut its price target to $1,400. The company reported a 14% rise in net sales to $2.285 billion for the fiscal first quarter, but net income dropped nearly 10% to $445 million due to higher interest expenses. TransDigm raised its 2026 profit forecast but kept the midpoint below analyst expectations.
4 February 2026
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 17.01.2026

TransDigm Group reported $8.83 billion in revenue and $1.87 billion net income, with shares near $1,450 and a P/E of 43.8x. Elevance Health closed at $374.87, with DCF analysis suggesting a 62.9% undervaluation. BlackRock traded at $1,163.17, about 11.6% above its implied value. Commercial Metals ended at $74.42, with DCF pointing to a 37.3% discount to intrinsic value.
17 January 2026
···

Stock Market Today

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop